Moffitt Cancer Center Logo
 

Jonathan R. Strosberg, MD

Where You Are:
Jonathan R. Strosberg, MD

Associate Member

Office  (888) 860-2778

Education And Training
  • Fellow, H. Lee Moffitt Cancer Center & Research Institute, 2006 - Medical Oncology & Hematology
  • Resident, Georgetown University Hospital, 2001 - General Internal Medicine
  • MD, Cornell University Medical College, 1999
  • BA, Harvard University, 1995


Dr. Strosberg’s interests center on development and implementation of biomarker-driven therapeutics into patient-based therapeutic trials. Collaborative research led to the identification of new molecular prognostic markers (including palladin and RUNX1T1) associated with malignant progression of pancreatic neuroendocrine tumors.  His data on treatment of metastatic pancreatic endocrine carcinomas with the novel combination of capecitabine and temozolomide was recognized internationally. Dr. Strosberg and colleagues are analyzing whether deficiency of the O6 Methylguanine DNA Methyltransferase (MGMT) enzyme is predictive for response. He also completed a phase II study of hepatic artery embolization followed by sunitinib, a VEGF-receptor inhibitor.  Initial analysis showed that embolization causes a surge in serum VEGF which can potentially lead to rapid angiogenesis after embolization. He developed a multicenter phase II study of an IGF-receptor inhibitor for treatment of carcinoid and pancreatic neuroendocrine tumors to analyze whether upregulation of the IGF-R pathway predicts for response.  He also developed two investigator-initiated clinical trials of targeted therapy for metastatic colorectal cancer, including a phase IIB multicenter, randomized, placebo-controlled trial of a novel IGF-receptor inhibitor and a phase II NCI-supported study of a RO4929097, a gamma-secretase inhibitor.  Both trials incorporate predictive serum and immunohistochemical biomarkers pertaining to the Notch and insulin-like growth factor pathways.

  • Strosberg JR. Systemic Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS): Cuirrent Approaches and Future Options. Endocr Pract. 2014 Feb;20(2):167-175. Pubmedid: 24014009.
  • Grozinsky-Glasberg S, Thomas D, Strosberg JR, Pape UF, Felder S, Tsolakis AV, Alexandraki KI, Fraenkel M, Saiegh L, Reissman P, Kaltsas G, Gross DJ. Metastatic type 1 gastric carcinoid: A real threat or just a myth?. World J Gastroenterol. 2013 Dec;19(46):8687-8695. Pubmedid: 24379587.
  • Strosberg J. Evolving treatment strategies for management of carcinoid tumors. CURR TREAT OPTION ON. 2013 Sep;14(3):374-388. Pubmedid: 23892588.
  • Henderson-Jackson EB, Nasir A, Chen DT, Nandyala P, Djeu J, Strosberg J, Kvols L, Coppola D. Cytoplasmic Clusterin Expression Correlates With Pancreatic Neuroendocrine Tumor Size and Pathological Stage. Pancreas. 2013 Aug;42(6):967-970. Pubmedid: 23770713.
  • Strosberg J. Advances in the Treatment of Pancreatic Neuroendocrine Tumors (pNETs). Gastrointest Cancer Res. 2013 Jul;6(4 Suppl 1):S10-S12. Pubmedid: 24312683. Pmcid: PMC3849907.
  • Strosberg J, Chan J, Ryan DP, Meyerhardt JA, Fuchs CS, Abrams TA, Regan EM, Brady R, Weber J, Campos T, Kvols L, Kulke MH. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2013 Jun;20(3):383-390. Pubmedid: 23572164.
  • Strosberg J, Weber J, Feldman M, Goldman J, Almhanna K, Kvols L. Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors. Gastrointest Cancer Res. 2013 May;6(3):81-85. Pubmedid: 23936548. Pmcid: PMC3737510.
  • Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC. Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors. Pancreas. 2013 May;42(4):557-577. Pubmedid: 23591432.
  • Strosberg JR, Fisher GA, Benson AB, Malin JL, Cherepanov D, Broder MS. Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process. Pancreas. 2013 Apr;42(3):397-404. Pubmedid: 23211372.
  • Strosberg J, Casciano R, Stern L, Parikh R, Chulikavit M, Willet J, Liu Z, Wang X, Grzegorzewski KJ. United States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatment. World J Gastroenterol. 2013 Apr;19(15):2348-2354. Pubmedid: 23613628.
  • Casciano R, Wang X, Stern L, Parikh R, Chulikavit M, Willet J, Liu Z, Strosberg J, Cadiot G, Riechelmann R. International practice patterns and resource utilization in the treatment of neuroendocrine tumors. Pancreas. 2013 Mar;42(2):339-347. Pubmedid: 23357923.
  • Strosberg JR. Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma. Semin Oncol. 2013 Feb;40(1):120-133. Pubmedid: 23391119.
  • Strosberg JR, Weber JM, Feldman M, Coppola D, Meredith K, Kvols LK. Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol. 2013 Feb;31(4):420-425. Pubmedid: 23248248.
  • Saranga-Perry V, Morse B, Centeno B, Kvols L, Strosberg J. Treatment of Metastatic Neuroendocrine Tumors of the Thymus with Capecitabine and Temozolomide: A Case Series. Neuroendocrinology. 2013 Jan. Pubmedid: 23296364.
  • Strosberg J. Neuroendocrine tumours of the small intestine. Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):755-773. Pubmedid: 23582917.
  • Naraev BG, Strosberg JR, Halfdanarson TR. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Oncology. 2012 Oct;83(3):117-127. Pubmedid: 22797357.
  • Almhanna K, Strosberg JR. Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol. 2012 Oct;18(40):5679-5687. Pubmedid: 23155307. Pmcid: PMC3484335.
  • Cheema A, Weber J, Strosberg JR. Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes. Ann Surg Oncol. 2012 Sep;19(9):2932-2936. Pubmedid: 22350605.
  • Strosberg JR, Weber JM, Choi J, Campos TL, Valone TL, Han G, Schell MJ, Kvols LK. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol. 2012 Sep;23(9):2335-2341. Pubmedid: 22317769.
  • Strosberg JR, Cheema A, Weber JM, Ghayouri M, Han G, Hodul PJ, Kvols LK. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg. 2012 Aug;256(2):321-325. Pubmedid: 22415420.
  • Metz DC, Choi J, Strosberg J, Heaney AP, Howden CW, Klimstra D, Yao JC. A rationale for multidisciplinary care in treating neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes. 2012 Aug;19(4):306-313. Pubmedid: 22760514.
  • Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA. Neuroendocrine tumors. J Natl Compr Canc Netw. 2012 Jun;10(6):724-764. Pubmedid: 22679117.
  • Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012 May;48(7):997-1003. Pubmedid: 22445247.
  • Dumont AG, Rink L, Godwin AK, Miettinen M, Joensuu H, Strosberg JR, Gronchi A, Corless CL, Goldstein D, Rubin BP, Maki RG, Lazar AJ, Lev D, Trent JC, von Mehren M. A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. Ann Oncol. 2012 May;23(5):1335-1340. Pubmedid: 21994214. Pmcid: PMC3493136.
  • Almhanna K, Strosberg J, Malafa M. Targeting AKT protein kinase in gastric cancer. Anticancer Res. 2011 Dec;31(12):4387-4392. Pubmedid: 22199303.
  • Henderson-Jackson EB, Helm J, Strosberg J, Nasir NA, Yeatman TJ, Kvols LK, Coppola D, Nasir A. Palladin is a marker of liver metastasis in primary pancreatic endocrine carcinomas. Anticancer Res. 2011 Sep;31(9):2957-2962. Pubmedid: 21868544.
  • O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, Sebti SM, Sullivan DM. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2011 Aug;29(17):2350-2356. Pubmedid: 21519015. Pmcid: PMC3107750.
  • Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol. 2011 Aug;29(22):3044-3049. Pubmedid: 21709192.
  • Nasir A, Helm J, Turner L, Chen DT, Strosberg J, Hafez N, Henderson-Jackson EB, Hodul P, Bui MM, Nasir NA, Hakam A, Malafa MP, Yeatman TJ, Coppola D, Kvols LK. RUNX1T1: a novel predictor of liver metastasis in primary pancreatic endocrine neoplasms. Pancreas. 2011 May;40(4):627-633. Pubmedid: 21499216.
  • Strosberg JR, Cheema A, Kvols LK. A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control. 2011 Apr;18(2):127-137. Pubmedid: 21451455.
  • Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011 Mar;117(2):268-275. Pubmedid: 20824724.
  • Ghayouri M, Boulware D, Nasir A, Strosberg J, Kvols L, Coppola D. Activation of the serine/theronine protein kinase Akt in enteropancreatic neuroendocrine tumors. Anticancer Res. 2010 Dec;30(12):5063-5067. Pubmedid: 21187491.
  • Anthony LB, Strosberg JR, Klimstra DS, Maples WJ, O'Dorisio TM, Warner RR, Wiseman GA, Benson AB, Pommier RF. The NANETS Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors (NETs): Well-Differentiated NETs of the Distal Colon and Rectum. Pancreas. 2010 Aug;39(6):767-774. Pubmedid: 20664474.
  • Phan AT, Oberg K, Choi J, Harrison LH, Hassan MM, Strosberg JR, Krenning EP, Kocha W, Woltering EA, Maples WJ. NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Thorax (Includes Lung and Thymus). Pancreas. 2010 Aug;39(6):784-798. Pubmedid: 20664476.
  • Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010 Aug;39(6):799-800. Pubmedid: 20664477. Pmcid: PMC3100733.
  • Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol. 2010 Jun;16(24):2963-2970. Pubmedid: 20572298. Pmcid: PMC2890935.
  • Barthel JS, Kucera ST, Lin JL, Hoffe SE, Strosberg JR, Ahmed I, Dilling TJ, Stevens CW. Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?. Gastrointest Endosc. 2010 Feb;71(2):235-240. Pubmedid: 20003971.
  • Strosberg J, Nasir A, Coppola D, Wick M, Kvols L. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol. 2009 Sep;40(9):1262-1268. Pubmedid: 19368957.
  • Strosberg JR, Hammer GD, Doherty GM. Management of adrenocortical carcinoma. J Natl Compr Canc Netw. 2009 Jul;7(7):752-758. Pubmedid: 19635227.
  • Kvols LK, Turaga KK, Strosberg J, Choi J. Role of interventional radiology in the treatment of patients with neuroendocrine metastases in the liver. J Natl Compr Canc Netw. 2009 Jul;7(7):765-772. Pubmedid: 19635229.
  • Clark OH, Benson AB, Berlin JD, Choti MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kessinger A, Kulke MH, Kvols L, Salem R, Saltz L, Shah MH, Shibata S, Strosberg JR, Yao JC. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw. 2009 Jul;7(7):712-747. Pubmedid: 19635226.
  • Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. Pancreas. 2009 Apr;38(3):255-258. Pubmedid: 19066493.
  • Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology. 2009 Jan;89(4):471-476. Pubmedid: 19174605.
  • Hodul P, Strosberg J, Kvols L. Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated. Cancer Control. 2008 Oct;15(4):314-321. Pubmedid: 18813199.
  • Strosberg JR, Nasir A, Hodul P, Kvols L. Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res. 2008 May;2(3):113-125. Pubmedid: 19259290.
  • Nasir A, Gardner N, Strosberg J, Ahmad N, Choi J, Malafa M, Coppola D, Kwekkeboom D, Teunissen J, Kvols L. Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels. Pancreas. 2008 Apr;36(3):309-313. Pubmedid: 18362846.
  • Strosberg J, Hoffe S, Gardner N, Choi J, Kvols L. Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy. Neuroendocrinology. 2007 Sep;85(4):216-220. Pubmedid: 17541257.
  • Strosberg J, Nasir A, Cragun J, Gardner N, Kvols L. Metastatic carcinoid tumor to the ovary: A clinicopathologic analysis of seventeen cases. Gynecol Oncol. 2007 Jul;106(1):65-8. Pubmedid: 17475313.
  • Strosberg J, Kvols L. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs. 2007 Feb;16(2):219-224. Pubmedid: 17243941.
  • Strosberg JR, Shibata D, Kvols LK. Intermittent bowel obstruction due to a retained wireless capsule endoscope in a patient with a small bowel carcinoid tumour. Can J Gastroenterol. 2007 Feb;21(2):113-115. Pubmedid: 17299616. Pmcid: PMC2657671.
  • Strosberg J, Hoffe S, Hazelton T, Kvols L. External beam irradiation of myocardial carcinoid metastases: a case report. J Med Case Rep. 2007;1:95. Pubmedid: 17880715. Pmcid: PMC2040153.
  • Osborne D, Zervos E, Strosberg J, Boe B, Malafa M, Rosemurgy A, Yeatman TJ, Carey L, Duhaine L, Kvols L. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006 Apr;13(4):572-581. Pubmedid: 16511671.
  • Strosberg J, Choi J, Cantor A, Kvols L. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control. 2006 Jan;13(1):72-78. Pubmedid: 16508629.
  • Nasir A, Stridsberg M, Strosberg J, Su P, Livingston S, Malik H, Kelley ST, Centeno B, Coppola D, Malafa M, Yeatman T, Kvols L. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. Cancer Control. 2006 Jan;13(1):52-60. Pubmedid: 16508627.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer